Matching trials
2,411 results
- Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease: Complete Statistical AnalysisIndependent statistical analysis of Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- FSHDIndependent statistical analysis of Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT): Complete Statistical AnalysisIndependent statistical analysis of Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- FX-322 in Sensorineural Hearing Loss: Complete Statistical AnalysisIndependent statistical analysis of FX-322 in Sensorineural Hearing Loss: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03616223).
- FX-LEARNIndependent statistical analysis of AFQ056 for Language Learning in Children With FXS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02920892).
- G-Pen™ for Hypoglycemia Rescue in T1D Patients: Complete Statistical AnalysisIndependent statistical analysis of G-Pen™ for Hypoglycemia Rescue in T1D Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02423980).
- Gabapentin Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients: Complete Statistical AnalysisIndependent statistical analysis of Gabapentin Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00420771).
- GALAHADIndependent statistical analysis of the GALAHAD phase 2 study of niraparib in men with metastatic castration-resistant prostate cancer and DNA-repair anomalies, including its single-group design, binary objective response endpoint, RECIST 1.1 and…
- GALAXYComplete statistical analysis of the GALAXY phase 1/2 clinical trial evaluating targeted antibody-drug conjugates for HER2 ultra-low or no expression advanced breast cancer, including design, endpoints, statistical methodology, planned analyses, and interpretation.
- GAMES-PILOTIndependent statistical analysis of Glyburide Advantage in Malignant Edema and Stroke Pilot: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01268683).
- Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study: Complete Statistical AnalysisIndependent statistical analysis of Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00129441).
- GammozIndependent statistical analysis of Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- GARGLESIndependent statistical analysis of Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus: Complete Statistical AnalysisIndependent statistical analysis of Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02170870).
- GATEWAYIndependent statistical analysis of A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- GATSBYA complete statistical analysis and educational interpretation of the GATSBY phase 1/2 trial of gevokizumab for scleritis, including its single-group design, ordinal scleral inflammation endpoint, planned statistical approach, and reported safety.
- GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD): Complete Statistical AnalysisIndependent statistical analysis of GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Gemcabene for the Treatment of Pediatric NAFLD: Complete Statistical AnalysisIndependent statistical analysis of Gemcabene for the Treatment of Pediatric NAFLD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03436420).
- Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00388154).
- Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery: primary endpoint results, effect estimate with confidence interval, sample-size…
- Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence…
- Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery: primary endpoint results, effect estimate with confidence interval,…
- Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01459614).
- GEMINIIndependent statistical analysis of A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) – Retinitis Pigmentosa GTPase Regulator (RPGR): Complete Statistical AnalysisIndependent statistical analysis of Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy: Complete Statistical AnalysisIndependent statistical analysis of Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Genetic Effects on Dopamine Response to an Opiate: Complete Statistical AnalysisIndependent statistical analysis of Genetic Effects on Dopamine Response to an Opiate: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01878006).
- GeniProIndependent statistical analysis of Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream: Complete Statistical AnalysisIndependent statistical analysis of Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Gentamicin Bladder Instillations to Prevent Urinary Tract Infections in Patients With Spinal Cord Injury: Complete Statistical AnalysisIndependent statistical analysis of Gentamicin Bladder Instillations to Prevent Urinary Tract Infections in Patients With Spinal Cord Injury: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- GeparSixtoIndependent statistical analysis of GeparSixto (NCT01426880), a randomized phase 2/3 trial evaluating addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer.
- Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size…
- GLIDERIndependent statistical analysis of A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS): primary endpoint results, effect estimate…
- GLIMPIndependent statistical analysis of Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19): Complete Statistical AnalysisIndependent statistical analysis of GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Glucagon Response to Prandial Insulin Administration in Persons With Type 1 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Glucagon Response to Prandial Insulin Administration in Persons With Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Glucose Regulation in Acute Stroke Patients (GRASP) Study: Complete Statistical AnalysisIndependent statistical analysis of Glucose Regulation in Acute Stroke Patients (GRASP) Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00282867).
- Glutamine for the Prevention of Radiation Toxicity in Subjects Conserving Therapy: Complete Statistical AnalysisIndependent statistical analysis of Glutamine for the Prevention of Radiation Toxicity in Subjects Conserving Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment: Complete Statistical AnalysisIndependent statistical analysis of Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment: primary endpoint results, effect estimate with confidence interval, sample-size…
- GRABM-LIndependent statistical analysis of GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- GRAY-BIndependent statistical analysis of GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- GRECCAR-4Independent statistical analysis of GRECCAR-4, a randomized phase 2 trial evaluating a tailored strategy for locally advanced rectal carcinoma, including its design, R0 resection endpoint, planned statistical analysis, and interpretation.